Vincent Aurentz - 21 Feb 2025 Form 4/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ David McIntyre, attorney-in-fact
Issuer symbol
IKT
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
02 Jul 2025, 19:55:37 UTC
Date Of Original Report
25 Feb 2025
Previous filing
02 Dec 2024
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aurentz Vincent Director 1000 N. WEST STREET, SUITE 1200, WILMINGTON /s/ David McIntyre, attorney-in-fact 02 Jul 2025 0001657494

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +134,427 $0.000000 134,427 21 Feb 2025 Common Stock 134,427 $2.97 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.
F2 The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.